Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP-Hib-IPV-Novartis Vaccines-meningococcal group B infection
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP-Hib-IPV-Novartis Vaccines-meningococcal group B infection refers to a clinical trial regimen involving the co-administration of Novartis's multicomponent meningococcal serogroup B vaccine (4CMenB, brand name Bexsero) alongside a routine pediatric combination vaccine (DTaP-Hib-IPV). Bexsero is a recombinant protein vaccine containing four primary antigens: factor H binding protein (fHbp), Neisserial adhesin A (NadA), Neisseria heparin binding antigen (NHBA), and outer membrane vesicles (OMV) from the NZ98/254 strain. It is designed to elicit bactericidal antibodies against Neisseria meningitidis serogroup B. The DTaP-Hib-IPV component is a pentavalent vaccine providing protection against diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and poliomyelitis. This specific co-administration protocol was evaluated in Phase 2 studies to assess the safety, tolerability, and immunogenicity of the MenB vaccine when integrated into the standard infant immunization schedule.
- Other names
- Bexsero + DTaP-Hib-IPV4CMenB + DTaP-Hib-IPVrMenB+OMV + DTaP-Hib-IPV
02
Targets
Poliovirus capsid proteinsPRN (Pertactin)FIM2/FIM3 (Fimbriae types 2 and 3)Neisseria meningitidis serogroup B outer membrane antigensHBsAg (Hepatitis B surface antigen)PRNP (Cellular Prion Protein)FHA (Filamentous hemagglutinin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on DTaP-Hib-IPV-Novartis Vaccines-meningococcal group B infection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP-Hib-IPV-Novartis Vaccines-meningococcal group B infection.